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Tuberculosis (TB) is an airborne infection caused byMycobacterium tuberculosis (Mtb). About one-third of the world’s population
is latently infected with TB and 5–15% of themwill develop active TB in their lifetime. It is estimated that each case of active TBmay
cause 10–20 new infections. Host immune response to Mtb is inﬂuenced by interferon- (IFN-) signaling pathways, particularly by
type I and type II interferons (IFNs). The latter that consists of IFN-γ has been associated with the promotion of Th1 immune
response which is associated with protection against TB. Although this aspect remains controversial at present due to the lack of
established correlates of protection, currently, there are diﬀerent prophylactic, diagnostic, and immunotherapeutic approaches in
which IFNs play an important role. This review summarizes the main aspects related with the biology of IFNs, mainly
associated with TB, as well as presents the main applications of these cytokines related to prophylaxis, diagnosis, and
immunotherapy of TB.
1. Introduction
1.1. Tuberculosis. Mycobacterium tuberculosis (Mtb) is a
human-restricted pathogen which causes tuberculosis (TB).
TB is one of the most common infections worldwide, mostly
aﬀecting individuals in low- and middle-income countries
[1]. In 2015, 10.4 million cases of TB and more than 1.8
million deaths were reported [1]. About 2 billion people are
latently infected with TB worldwide (about one-third of the
world’s population) and 5–15% of them will develop TB in
their lifetime [2]. It is predicted that in the next 20 years, an
additional 1 billion people will be infected with TB and 35
million will die unless eﬀective preventive means are pro-
vided [3]. TB is an airborne disease transmitted by inhalation
of Mtb-containing aerosol droplets from infected secretions
of the respiratory airways [4]. Once inhaled, Mtb is phagocy-
tized by alveolar macrophages and has the ability to survive
and replicate inside these cells in a modiﬁed phagosomal
compartment for decades. A strong cell-mediated immune
response can eﬀectively inhibit bacterial replication in
latently infected individuals [5]. Although the human
immune system can control the infection, the prevalence of
TB is being sustained by two important factors, that is, (1)
human immunodeﬁciency virus (HIV) infection and (2) the
presence of multidrug-resistant (MDR) strains of Mtb [1].
In 2015, about 35% of HIV-infected patients died due to coin-
fection with TB [1]. These immunocompromised individuals
developed active TB due to failure of their immune system to
control or eradicate the infection [6]. Additionally, it was esti-
mated that 480,000 people developed multidrug-resistant TB
(MDR-TB) in 2015 [1]. It is reported that interferon- (IFN-)
mediated innate and adaptive immune responses are involved
in the host immune response against TB [7, 8].
1.2. Types of Interferons. IFNs are cytokines that carry signals
between cells [9]. Generally, IFNs are diﬀerentiated accord-
ing to their molecular structure and classiﬁed into three
groups depending on the type of receptor through which they
signal. Type I IFNs consist of 13 subtypes of IFN-α, and
single subtypes of IFN-β, IFN-κ, IFN-ε, IFN-ω, and IFN-τ,
which bind to a receptor complex composed of two chains,
IFNAR1 and IFNAR2 [10]. IFN-γ is the only interferon clas-
siﬁed in type II IFN, and it binds to a receptor complex com-
posed of the IFNγR1 and IFN-γR2 subunits [11]. Type III
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IFNs consist of IFN-λ1 (IL-29), IFN-λ2 (IL-28A), IFN-λ3
(IL-28B), and IFN-λ4, which signals through a receptor com-
plex consisting of IL10R2 (also called CRF2-4) and IFNLR1
(also called CRF2-12) [12]. Type I IFNs are expressed upon
recognition of bacterial and viral components [13], and type
II IFN is induced by IL-12 and IL-2 stimulation [14], while
type III IFNs are induced by viral components [15]. This
shows that host responses are stimulated not only by pattern
recognition receptors but also by cytokine responses [13, 14].
IFNs are released by the host cells to regulate and activate
immune response [16]. Type I IFNs are produced by almost
every cell in the body (such as leukocytes, ﬁbroblasts, and
endothelial cells), while the type II IFN (also known as
immune interferon) is produced by T-cells (especially CD4+
T-cells) [17]. Type III IFN is produced mainly by epithelial
cells such as lung epithelial cells, hepatocytes, and tropho-
blastic cells [18]. When IFNs are released, they bind to diﬀer-
ent kinds of receptors which lie on the surface of cells before
being drawn into the cytoplasm [19]. This causes a series of
intracellular events involving other proteins inside the cell,
resulting in the activation of diﬀerent processes involved in
the response to infections [19] (Table 1).
1.3. Interferon Downstream Signaling. IFNs activate Janus-
activated kinase-signal transducer and activator of transcrip-
tion (JAK-STAT) signaling pathway to transmit information
from extracellular chemical signals to the nucleus resulting in
DNA transcription and expression of genes involved in
immunity, proliferation, diﬀerentiation, and apoptosis [20].
JAKs are intracellular, nonreceptor tyrosine kinases associ-
ated with types I, II, and III IFN receptors. When IFNs are
released, they bind to speciﬁc receptors which lie on the
surface of cells, activating JAKs which then autophosphory-
late tyrosine residues on the receptors and create binding
sites for STATs [20]. Types I and III IFNs activate STAT1
and STAT2, form heterodimers which combine with IFN
regulatory factor 9 (IRF9), and form IFN-stimulated gene
(ISG) factor 3 (ISGF3) complexes [20–22]. Also, types I, II,
and III IFNs can stimulate the formation of STAT1-STAT1
homodimers [20–22]. Both the ISGF3 complexes and the
STAT1-STAT1 homodimers are translocated into the
nucleus and induce expression of genes via the IFN-
stimulated response element (ISRE) or IFN-γ-activated site
(GAS) promoters, respectively [20–23]. Intracellular signal-
ing pathway for types I, II, and III IFNs are shown in
Table 1. In addition to JAK-STAT pathway, type I IFN-
activated JAKs can also activate other signaling pathways,
such as CRKL-STAT5 complexes, mitogen-activated protein
kinase (MAPK) p38, and mediate initiation of mRNA trans-
lation via phosphorylation of insulin-receptor substrates
(IRS1 and IRS2) [20].
2. Role of Interferon in Tuberculosis
2.1. Interferon-Mediated Immune Response in TB. Several
reports linked the Mtb-enhanced infection to IFN type I-
induced eﬀects [8, 24, 25]; in contrast, other reports in mice
and humans describe positive eﬀects and inhibition of
macrophage alternative activation favoring the protective
mechanisms against Mtb infection [26, 27]. Within a few
hours postinfection, during the early stage, both types I and
II IFNs are produced in similar quantities. This common
proinﬂammatory pathway act synergistically to induce an
optimal immune response to TB, in particular, the recruit-
ment, diﬀerentiation, and survival of dendritic cells and mac-
rophages in the lungs. These myeloid cells are able to
phagocytose and subsequently kill the pathogens acting as
the ﬁrst line of the immune defense system [8]. However, this
also indirectly promotes TB infection by providing target
cells (especially macrophages) for intracellular growth of
Mtb [8]. Mtb is able to evade macrophage responses and
develop immune escape mechanisms by inhibiting acidiﬁca-
tion/maturation of phagosomes and preventing phagosome-
lysosome fusion [28]. This enables Mtb to persist inside
macrophages, replicate, and spread to new host cells [28]. It
is reported that production of type I IFNs (IFN-α and
IFN-β) during TB infection help to promote the disease
[24, 25]. They induce the immunosuppressive/macrophage-
deactivating cytokine IL-10 and block Th1 immune response
and suppress host-protective cytokines such as TNF-α, IL-12,
and IL-1β [24, 25]. Also, when both types I and II IFNs are in
similar concentration, type I IFNs limit the expression of
IFN-γ-induced MHC class II on antigen-presenting cells
(APCs) [29].
Several days postinfection, the adaptive immune
response to TB is optimally activated, where CD4+ and
CD8+ eﬀector T-cells traﬃc to the lungs where they produce
IFN-γ [8]. At this stage, the concentration of IFN-γ would be
ten times higher compared to that of type I IFNs [8]. Many
studies have shown that IFN-γ driven Th1 responses are
crucial for the immune response in Mtb infection [8]. Since
Mtb is a pathogenic intracellular microorganism, Th1 type
cytokines play a major role in stimulating cell-mediated
immune responses for the development of host protection.
Under these conditions, IFN-γ becomes the predominant
immunomodulatory regulator by recruitment of T-cells,
induction of expression of MHC class II molecules, augmen-
tation of APCs, and control of Mtb growth [8]. In addition,
IFN-γ promotes cellular proliferation, cell adhesion, apopto-
sis, and autophagy [30]. IFN-γ increases mycobactericidal
activity in the infected macrophages by inducing respiratory
burst with production of reactive nitrogen intermediates
(RNI) and reactive oxygen intermediates (ROI) [31]. Type
III IFNs are not essential for Mtb infection control, but may
contribute to the modulation of Th1/Th2 immune responses
to this pathogen [25]. The concentration of type III IFNs had
been reported to be increased in the sputum of pulmonary
TB patients compared to that of latently infected and unin-
fected healthy individuals, which suggest the possibility of
the production of this cytokine by inﬂammatory cells under
the inﬂuence of Mtb products [32]. The balance between
IFN-γ and other cytokines, such as IL-10 and other Th2 cell
cytokines, is likely to inﬂuence the disease outcome [8]. Over-
all, IFNs seems to be important modulators of host immune
responses for protection against TB, and thus have been used
in diagnostic, therapeutic, and vaccination approaches. In the
following sections, we will review the diﬀerent applications
related to IFNs on these three categories (Table 1).
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2.2. Use of Interferons in Diagnosis. After infection with Mtb,
the bacteria are contained by the host immune system and
persist in subclinical status with minimal replication and no
clinical manifestations of the disease [33]. In this dormant
stage, also referred to as latent TB, the bacteria can persist
for decades [33]. In situations where the individual’s immu-
nologic status is compromised, Mtb may begin to replicate,
resulting in the reactivation of TB [34]. At this stage, the gold
Table 1: Comparison of type I, type II, and type III interferons.
Type I IFN Type II IFN Type III IFN
Source of stimulation
Bacterial and viral components
[13]
IL-12 and IL-2 [14] Viral components [15]
Source of production
Every cell in the body (leukocytes,
ﬁbroblasts, and endothelial cells)
[17]
T-cells (especially CD4+ T-cells)
[17]
Epithelial cells [18]
Type
IFN-α, IFN-β, IFN-κ, IFN-ε,
IFN-ω, and IFN-τ [10]
Only IFN-γ [11]
IFN-λ1 (IL-29), IFN-λ2
(IL-28A), IFN-λ3 (IL-28B), and
IFN-λ4 [12]
Receptor IFNAR1 and IFNAR2 [10] IFNγR1 and IFN-γR2 [11]
IL10R2 (also called CRF2-4) and
IFNLR1 (also called CRF2-12) [12]
Intracellular
signaling
JAK JAK1, TYK2 [20] JAK1, JAK2 [20] JAK1, TYK2 [21]
STAT STAT1, STAT2 [20] STAT1 [20] STAT1, STAT2 [21]
Translocation
complex to
nucleus
(i) IFN-stimulated gene factor 3
(ISGF3) [20]
(ii) STAT1-STAT1 homodimers
[20]
STAT1-STAT1 homodimers [20]
(i) IFN-stimulated gene factor 3
(ISGF3) [22]
(ii) STAT1-STAT1 homodimers [22]
Promoters
stimulated
(i) IFN-stimulated response
element (ISRE) [20]
(ii) IFN-γ-activated site (GAS)
[20, 23]
IFN-γ-activated site (GAS) [20]
(i) IFN-stimulated response element
(ISRE) [22]
(ii) IFN-γ-activated site (GAS) [22]
Function in
tuberculosis
(i) Induce the immunosuppres-
sive/macrophage-deactivating
cytokine, IL-10 [24, 25]
(ii) Either block [24, 25] or polarize
[26] Th1 immune response
(iii) Suppress host-protective
cytokines suchasTNF-α, IL-12,
and IL-1β [24, 25]
(iv) Limit the expression of IFN-γ-
inducedMHC class II on APCs
[29]
(v) Synergistic eﬀect with IFN type
II promoting protection against
Mtb infection in mice [8]
(vi) Inhibition of alternative
macrophage activation [27]
(i)StimulateTh1typecytokines[8]
(ii)RecruitmentofT-cells [8]
(iii) Inductionofexpressionof
MHCclass IImoleculesand
augmentationofAPCs[8]
(iv)Promotescellular
proliferation, cell adhesion,
apoptosis, andautophagy[30]
Not essential for Mtb infection
control, but may contribute to the
modulation of Th1/Th2 immune
responses [25]
Use in diagnosis No report
IFN-γ release assays (IGRAs)
[43–55]
No report
Use in therapeutics
Adjunctive therapy with IFN-α by
aerosol route to treat pulmonary
TB. Precaution need to be taken
while treating immunodeﬁciency
patients as it may lead to TB
reactivation [26, 27, 64–70]
Adjunctive therapy with IFN-γ
by aerosol or subcutaneous routes
to treat pulmonary TB or
extrapulmonary TB [58–63]
No report
Use in vaccine
Combination of IFN-α and IFN-γ
enhance production of IL-12
which induce CD4+ T-cell Th1
polarization [71]
(i) Use as adjuvant to induce Th1
immunity [73, 74]
(ii) Development of fusion
proteins, genetic
constructions, or live vectors
expressing cytokines related
to the induction of IFN-γ
[75–113]
No report
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standard for diagnosis of active TB is the bacteriologically
conﬁrmatory test using sputum as biological sample [35].
However, direct acid-fast microscopy using Ziehl-Neelsen
staining has low sensitivity (requires approximately 5000–
10,000 bacilli per 1mL sputum for detection), and culture is
laborious and time consuming, taking between 2 and 8 weeks
to give a positively result [36]. Alternatively, a faster way of
identiﬁcation can be achieved using nucleic acid ampliﬁca-
tion tests (NAATs) [37]. Both tests require sputum which is
not always available (especially in infants and young
children) [38].
The latent TB diagnosis is of paramount importance
from the epidemiological point of view as it allows the
treatment to prevent the risk of future development of
active TB by 60–90%. Such treatment could avoid the esti-
mated 20–30 new infections that are produced from each
active TB case [39].
Currently, only two diagnostic methods are used to diag-
nose latent TB, that is, tuberculin skin test (TST) and IFN-γ
release assays (IGRAs) [40]. TST (also known as the Man-
toux test) was developed more than 100 years ago. Puriﬁed
protein derivative (PPD), a crude mixture of the culture ﬁl-
trate of Mtb, is used for intradermal injection on the forearm
of the individual, followed by the measurement of the indura-
tion produced at the site of injection after 48 to 72 hours [41].
The results are expressed as the size of the induration in the
site of injection after this period [40]. Depending on the risk
group of the individual, diﬀerent cut-oﬀ values for positivity
are established [40]. False-positive results are reported by this
test due to the presence in the PPD preparation, of nonspe-
ciﬁc antigens, which generate false-positive results associated
with previous BCG vaccination, and contact with environ-
mental mycobacteria [42]. Another drawback of this test is
the high rate of false-negative results in immunosuppressed
individuals [42].
Numerous studies have shown that one of the impor-
tant hallmarks of the immune response to Mtb infection
is the release of IFN-γ by T-cells [8]. Based on the pres-
ence of signiﬁcant IFN-γ responses upon Mtb infection,
the evaluation of the response of immune cells to speciﬁc
Mtb antigens has been used as an indicator of TB infec-
tion in diagnostic methods known as the IFN-γ release
assays (IGRAs) [43, 44]. There are two types of commer-
cial IGRAs available, that is, (1) T-SPOT.TB assay (Oxford
Immunotec, UK), an enzyme-linked immunosorbent spot
(ELISPOT) test that uses peripheral blood mononuclear cells
and (2) QuantiFERON-TB Gold In-Tube assay (Cellestis
Ltd., Australia), an enzyme-linked immunosorbent assay
(ELISA) that uses whole blood [43, 44]. Both assays use
speciﬁc stimulating antigens fromMtb, that is, culture ﬁltrate
protein 10 (CFP-10) and early secretory antigenic target 6
(ESAT-6), with an additional antigen, TB7.7, included in
the QuantiFERON-TB test [45]. When sensitized, mem-
ory/eﬀector T-cells from a blood sample, incubated with
these proteins, are stimulated to produce IFN-γ, and the
results are measured after 8 hours (T-SPOT.TB) or 16 hours
(QuantiFERON-TB Gold) [45]. T-SPOT.TB is more sensitive
(92.0–94.1%) than QuantiFERON-TB (83.0–89.0%) in
detecting pulmonary TB patients, and the latter has a poor
sensitivity in individuals more than 60 years old [46, 47].
Even though the assays are speciﬁc for Mtb and are not inﬂu-
enced by previous BCG vaccination, cross-reactivity have
been observed towards some non-TB strains, such as M.
ﬂavescens, M. kansasii, M. szulgai, and M. marinum [48].
False-negative results may occur in HIV-infected and immu-
nosuppressed patients as they are unable to mount a satisfac-
tory T-cell response, and their production of IFN-γ is low
[49]. Even though, IGRAs are reported to have higher sensi-
tivity and speciﬁcity compared to TST [50, 51]. IGRAs is not
fully suitable for children under the age of ﬁve as insuﬃcient
IFN-γ is produced at this age group [52]. However, a recent
study reported IFN-γ production in young children resulting
in slightly more sensitivity of IGRAs compared to that of TST
[53]. Although both TST and IGRAs cannot diﬀerentiate
between latent and active TB, diﬀerential diagnosis can be
done through clinical and radiologic evaluation [54]. Despite
the advantages of using IGRAs as diagnostic tests for latent
TB, their future prospects remain uncertain in low- and
middle-income countries since they have comparable perfor-
mance with TST but with higher cost and complexity [55].
2.3. Use of Interferons in Therapy. In low-resource settings,
inconsistent drug supply and weak TB-control infrastructure
can lead to the generation of TB-drug resistance [56]. Once
an Mtb strain develops resistance to ﬁrst-line antibiotics
(at least isoniazid, rifampicin), it is deﬁned as MDR-TB
[56, 57]. XDR-TB involves MDR-TB, with resistance to
any ﬂuoroquinolones and at least one of the injectable
second-line drugs [56, 57]. The second-line treatments
are less potent and less tolerable compared to ﬁrst-line
treatments, and the usage of these drugs is associated with
adverse side-eﬀects and the possibility of lung resection
surgery [56].
As alternative treatment of drug resistance TB, therapeu-
tic approaches using IFN-γ have been reported [58]. IFN-γ is
a heterogeneous glycoprotein with molecular weight ranging
from 34 to 50 kDa [59]. As stated previously, IFN-γ is an
important modulator for Th1 immune responses and proba-
bly plays an important role in conferring protection against
Mtb [8]. Therefore, it is conceivable that recombinant IFN-
γ could be used for treatment of TB [58]. Condos et al. [58]
conducted a study by treating pulmonary TB patients who
did not respond to their treatment with IFN-γ via aerosol.
Using aerosol administration, IFN-γ can safely be delivered
to the lower respiratory tract without systemic side eﬀects
[58]. The treatment helped to decrease the bacterial burden
in the lungs, where the patients’ sputum smears became neg-
ative during the 4-week intervention, and some patients even
showed diminished cavitary lesions (suggesting that IFN-γ
has antiﬁbrotic eﬀect) [58]. However, the eﬀect of exogenous
IFN-γ was short lived as sputum smears became positive
after 1 to 5 months upon discontinuation of treatment [58].
These results highlighted the need to study IFN-γ as long-
term therapy while evaluating its adverse side eﬀects, tolera-
bility, and therapeutic eﬀects [58]. According to Gao et al.
[60], even after 6 months of IFN-γ treatment to prevent
relapse, no substantial side eﬀects were observed, and adjunc-
tive therapy with IFN-γ by aerosol help to improve chest
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radiographic alterations, in contrast to IFN-γ administered
intramuscularly or subcutaneously. One report however
demonstrated positive outcome of intramuscular administra-
tion of IFN-γ in pulmonary MDR-TB although deﬁnitive
conclusions could not be drawn due to the small number of
patients studied [61]. Another study demonstrated no signif-
icant improvements in clinical, radiographic, microbiologic,
or immunologic parameters when IFN-γ was administered
subcutaneously in chronic and advanced MDR-TB patients
[62]. In contrast, a patient with acute lymphocytic leukemia,
who had refractory brain MDR-TB and did not respond to
anti-TB drugs and steroid treatment for 11 months, showed
improvement in brain and chest radiographic alterations
after 5 months of adjunctive therapy with IFN-γ adminis-
tered subcutaneously; and complete resolution of the lesions
in the brain and spinal cord were obtained after 12 months of
therapy [63]. Overall, these studies showed that adjunctive
therapy with IFN-γ by aerosol, intramuscular, or subcutane-
ous routes could be useful to treat MDR-TB patients, but fur-
ther controlled clinical trials are needed in order to establish
the role of IFN-γ in the treatment of TB [58, 60–63].
Other studies have reported that adjunctive therapy using
IFN-α was useful in the treatment of TB patients [64, 65].
IFN-α combined with antimycobacterial therapy showed
favorable results in treating pulmonary TB via aerosol
administration [64, 65] and in diabetic MDR-TB patients
via intramuscular injection [66]. This is probably because
IFN-α helps to induce Th1 polarization in responding T-
cells and increased production of IFN-γ [26]. Also, type I
IFNs can confer protection against Mtb infection in mice in
the absence of IFN-γ signaling by inhibiting alternative mac-
rophage activation, which, when present, may increase the
host susceptibility to TB [27]. Although low concentrations
of type I IFNs seem to be required during the early stages
of bacterial infection to initiate adaptive immune responses,
high concentration of type I IFNs may induce Th2 immune
responses, enhance production of immunosuppressive mole-
cules, and reduce responsiveness of macrophages to activa-
tion by IFN-γ [67]. This suggest that the concentration of
type I IFNs administered should be monitored if incorpo-
rated in a therapeutic schedule. Previous studies have also
shown that PEGylated-IFN-α therapy, which is the ﬁrst-
line choice of treatment for chronic hepatitis B, C, and D,
induces weight loss and anorexia and indirectly increases
the risk of TB reactivation, resulting in severe pulmonary
TB [68–70]. Thus, individuals who come from high-risk
countries should be tested for immunodeﬁciency (depletion
of CD4+ T-cells) or latent TB prior to IFN-α therapy to pre-
vent TB reactivation.
2.4. Use of Interferons in Vaccines. The use of IFNs in TB
vaccine development has been dominated by IFN-γwith very
little reports directly related to other IFNs.
2.4.1. IFN-α. The importance of the combined inﬂuence of
IFN-α and IFN-γ on human neonatal monocyte-derived
dendritic cells to induce the production of IL-12 as an impor-
tant element for the shift towards a CD4+ T-cell Th1
polarization has been advocated as one of the main eﬀects
of BCG vaccination [71].
In an application not directly related to TB vaccine devel-
opment, BCG expressing IFN-α-2b has been developed as an
experimental immunotherapeutic alternative to BCG for
bladder cancer. BCG secreting IFN-α-2b induced higher
levels of IFN-γ, TNF-α, IL-12, and lymphoproliferation as
well as increased antiproliferative and cytotoxic eﬀect on
bladder cancer cells in vitro [72].
2.4.2. IFN-γ. The two main applications of IFNs on TB vac-
cine development are (1) the use of IFN-γ directly as adju-
vant and (2) the use of vaccine candidates designed to
induce the production of this cytokine after immunization.
(1) IFN-γ as Adjuvant. Administration of an optimal IFN-γ
dose has been shown to enhance Th1-type immunity
induced by Ribi adjuvant, resulting in an improved response
against a cocktail of several Mtb antigens. However, the adju-
vant eﬀect of IFN-γ was dose dependent. A dose of 5μg of
IFN-γ per mouse per immunization gave optimal protection,
whereas lower or higher amounts (0.5 or 50μg/mouse) of
IFN-γ failed to enhance protection [73]. In another approach,
using recombinant BCG coexpressing Ag85B, ESAT-6, and
mouse-IFN-γ, an eﬀective protection against Mtb was
achieved in C57BL/6 mice [74].
(2) Vaccine-Induced IFN-γ. Vaccine candidates based on dif-
ferent technological platforms have been designed to elicit
the production of IFN-γ after immunization; among the
most relevant strategies is the use of IFN-γ inducing recom-
binant cytokines as adjuvant, fusion proteins, genetic con-
structions with cytokines, or live vectors expressing
cytokines related to the induction of IFN-γ.
The use of IL-12 and other cytokines for the induction of
Th1 immune responses via induction of IFN-γ have also
been attempted in experimental studies of TB vaccine devel-
opment [75]. The combination of IL-12 with BCG vaccina-
tion induced an increase in IFN-γ production and
protection compared to BCG in challenge experiments with
Mtb in mice [76]. Similarly, DNA immunization protocols
incorporating the IL-12 gene either separately or fused with
diﬀerent Mtb antigens and combined with BCG vaccination
induced signiﬁcant levels of IFN-γ and protection against
Mtb in challenge experiments in mice [77–80]. Likewise,
recombinant M. smegmatis and BCG expressing Mtb anti-
gens and IL-12 induced increased production of IFN-γ and
protection against Mtb in mice [81, 82].
IL-15 is another cytokine implicated in the induction of
IFN-γ production which had been used in experimental vac-
cines against TB [83]. The immunization with recombinant
BCG secreting a fusion protein composed of IL-15 and
Ag85B in mice was associated with IFN-γ production and
protection upon challenge with Mtb [84]. In another
approach, the combination of ﬁve Mtb antigens with IL-15
expressed in Modiﬁed Vaccinia Ankara in diﬀerent prime-
boost schedules induced the production of IFN-γ and
protection against Mtb in mice [85].
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IL-21 has been reported as an important element in
the protection against TB and is associated with the induc-
tion of IFN-γ production [86]. DNA vaccination inducing
the expression of fusion proteins containing Mtb antigens
and IL-21 enhanced the production of IFN-γ and protec-
tion against TB in mice in a prime-boost schedule with
BCG [87, 88].
IL-23 is another cytokine involved in the induction of
IFN-γ that has been used in the development of experimental
vaccines against TB [89, 90]. Plasmids containing the IL-23
gene administered with DNA vaccines including Mtb anti-
gens increase the production of IFN-γ and protection against
TB induced by the immunization with such vaccines [90].
Autophagy is a mechanism of great importance in the
defense against TB [91–93], which supported the implemen-
tation of strategies to exploit this phenomenon in TB vaccine
development [94–96]. Lactic acid bacteria together with Mtb
antigens increased the autophagy of human mononuclear
phagocytes by increasing IFN-γ and nitric oxide (NO) levels
together with the inhibition of Th2 cytokines involved in the
blockage of autophagy [94]. DNA vaccines incorporating
autophagy inducers increase the production of IFN-γ and
the protection against TB in mice [95, 96].
The induction of apoptosis is another strategy explored
for the control of Mtb infections, and, in fact, the evasion of
apoptosis is suggested to be one of the main strategies for
Mtb to escape the immune response [97–100]. Hence, several
approaches to TB vaccine development employing the use of
proapoptotic vaccine candidates in the form of DNA vaccine,
recombinant Mtb, or recombinant BCG platforms have been
tested, demonstrating the induction of IFN-γ production and
protection against Mtb in mice [101–104].
Other strategies directed to improve the Th1 immune
responses in TB vaccine development had been attempted.
IgG immunocomplexes containing Mtb antigens or IgG Fc
fusions with multistage antigens fromMtb, aimed to increase
the interaction with APCs, have been tested in mice which
induced protection associated with increase of IFN-γ
production [105, 106].
Although numerous studies have suggested the positive
association between the induction of IFN-γ responses and
protection against TB, several studies have failed to demon-
strate such a correlation. Some studies even demonstrated
detrimental eﬀects of IFN-γ on protection [107–113]. These
contradictory ﬁndings highlight the lack of a reliable corre-
late of protection for TB, which reﬂects the current eﬀorts
to determine more robust and consistent correlates of protec-
tion for this disease [108].
3. Conclusions
Interferons, especially IFN-γ, are important immunomodu-
lators in the pathogenesis of Mtb. It helps to activate macro-
phages and promote a range of cell-mediated immune
mechanisms. IFN-γ production in infected individuals has
been used, as a key element in IGRAs, and represents a
valuable tool for the speciﬁc detection of latent TB. IFN-γ
has also been used as adjuvant therapy in TB patients when
conventional therapy failed. Besides IFN-γ, another cytokine,
IFN-α, an important signaling protein to recruit myeloid
cells during innate immunity, has also been used as adjunc-
tive therapy in TB, but its potential for treatment remains
uncertain. In the TB vaccine area, the use of IFN-γ as adju-
vant or strategies that induce the production this cytokine
has been the most popular approach used to induce Th1
polarization and protection, although the role of IFN-γ as
TB correlate of protection is still debatable.
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